Literature DB >> 22318669

Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).

M V Joglekar1, P M Quintana Diez, S Marcus, R Qi, B Espinasse, M R Wiesner, E Pempe, J Liu, D M Monroe, G M Arepally.   

Abstract

Recent studies have shown that ultra-large complexes (ULCs) of platelet factor 4 (PF4) and heparin (H) play an essential role in the pathogenesis of heparin-induced thrombocytopenia (HIT), an immune-mediated disorder caused by PF4/H antibodies. Because antigenic PF4/H ULCs assemble through non-specific electrostatic interactions, we reasoned that disruption of charge-based interactions can modulate the immune response to antigen. We tested a minimally anticoagulant compound (2-O, 3-O desulfated heparin, ODSH) with preserved charge to disrupt PF4/H complex formation and immunogenicity. We show that ODSH disrupts complexes when added to pre-formed PF4/H ULCs and prevents ULC formation when incubated simultaneously with PF4 and UFH. In other studies, we show that excess ODSH reduces HIT antibody (Ab) binding in immunoassays and that PF4/ODSH complexes do not cross-react with HIT Abs. When ODSH and unfractionated heparin (UFH) are mixed at equimolar concentrations, we show that there is a negligible effect on amount of protamine required for heparin neutralisation and reduced immunogenicity of PF4/UFH in the presence of ODSH. Taken together, these studies suggest that ODSH can be used concurrently with UFH to disrupt PF4/H charge interactions and provides a novel strategy to reduce antibody mediated complications in HIT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318669      PMCID: PMC4441624          DOI: 10.1160/TH11-11-0795

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  29 in total

1.  Selectin-blocking semisynthetic sulfated polysaccharides as promising anti-inflammatory agents.

Authors:  M Höpfner; S Alban; G Schumacher; U Rothe; G Bendas
Journal:  J Pharm Pharmacol       Date:  2003-05       Impact factor: 3.765

2.  Neutralization of the antiheparin activity of platelet factor 4 by a monoclonal antibody.

Authors:  L Saggin; F Cazzola; G Corona; E Salvatico; G Cella; M Prosdocimi
Journal:  Thromb Haemost       Date:  1992-01-23       Impact factor: 5.249

Review 3.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

4.  Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Authors:  G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

5.  Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.

Authors:  Krystin Krauel; Christine Hackbarth; Birgitt Fürll; Andreas Greinacher
Journal:  Blood       Date:  2011-11-02       Impact factor: 22.113

6.  Cardiac surgery in a patient with heparin-induced thrombocytopenia--cautions with use of the direct thrombin inhibitor, argatroban.

Authors:  Viji Kurup; Sarah Transue; Yanyun Wu; Henry M Rinder; Paul Barash; Michael Dewar
Journal:  Conn Med       Date:  2006-04

7.  Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.

Authors:  K Krauel; B Fürll; T E Warkentin; W Weitschies; T Kohlmann; J I Sheppard; A Greinacher
Journal:  J Thromb Haemost       Date:  2008-10-03       Impact factor: 5.824

8.  Contribution of monosaccharide residues in heparin binding to antithrombin III.

Authors:  D H Atha; J C Lormeau; M Petitou; R D Rosenberg; J Choay
Journal:  Biochemistry       Date:  1985-11-05       Impact factor: 3.162

Review 9.  Orgaran (Org 10172): its pharmacological profile in experimental models.

Authors:  D G Meuleman
Journal:  Haemostasis       Date:  1992

10.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

View more
  12 in total

1.  2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia.

Authors:  Elizabeth Tkaczynski; Abinaya Arulselvan; John Tkaczynski; Stephen Avery; Liqing Xiao; Beverly Torok-Storb; Kraig Abrams; Narayanam V Rao; Gregory Johnson; Thomas P Kennedy; Mortimer Poncz; Michele P Lambert
Journal:  Blood Adv       Date:  2018-04-10

2.  Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies.

Authors:  Grace M Lee; Manali Joglekar; Maragatha Kuchibhatla; Sanjay Khandelwal; Rui Qi; Lubica Rauova; Gowthami M Arepally
Journal:  Blood Adv       Date:  2017-04-18

Review 3.  HITs and misses in 100 years of heparin.

Authors:  Lawrence Rice
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.

Authors:  Tibor J Kovacsovics; Alice Mims; Mohamed E Salama; Jeremy Pantin; Narayanam Rao; Ken M Kosak; Peter Ahorukomeye; Martha J Glenn; Michael W N Deininger; Kenneth M Boucher; Linda M Bavisotto; Gerardo Gutierrez-Sanchez; Thomas P Kennedy; Stephen G Marcus; Paul J Shami
Journal:  Blood Adv       Date:  2018-02-27

5.  Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia.

Authors:  Bruce S Sachais; Ann H Rux; Douglas B Cines; Serge V Yarovoi; Lee I Garner; Stephen P Watson; Jillian L Hinds; John J Rux
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

Review 6.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

Review 7.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

8.  Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia.

Authors:  Jing Dai; Daria Madeeva; Vincent Hayes; Hyun Sook Ahn; Valerie Tutwiler; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz; Lubica Rauova
Journal:  Blood       Date:  2018-06-18       Impact factor: 25.476

9.  Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.

Authors:  M Margaret Prechel; Jeanine M Walenga
Journal:  Thromb J       Date:  2013-04-05

10.  Early low-anticoagulant desulfated heparin after traumatic brain injury: Reduced brain edema and leukocyte mobilization is associated with improved watermaze learning ability weeks after injury.

Authors:  Katsuhiro Nagata; Yujin Suto; John Cognetti; Kevin D Browne; Kenichiro Kumasaka; Victoria E Johnson; Lewis Kaplan; Joshua Marks; Douglas H Smith; Jose L Pascual
Journal:  J Trauma Acute Care Surg       Date:  2018-05       Impact factor: 3.697

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.